AORT
Get informed when a big investor buys or sells
+ FollowOvervalued by 128.9% based on the discounted cash flow analysis.
| Market cap | $1.14 Billion |
|---|---|
| Enterprise Value | $1.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 1.22 |
| Outstanding Shares | 48,541,000 |
| P/E Ratio | -390.94 |
|---|---|
| PEG | 35.4 |
| Price to Sales | 2.55 |
| Price to Book Ratio | 2.55 |
| Enterprise Value to Revenue | 3.12 |
| Enterprise Value to EBIT | 69.92 |
| Enterprise Value to Net Income | -466 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.93 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Cr...
Stockcircle shows 8 open-market insider sales for Artivion in the last six months from SEC Form 4 reports by executives, directors, and other insiders.
Stockcircle lists 2 politician trade disclosures tied to Artivion in the last twelve months, drawn from periodic financial disclosure reports. 1 politician traded Artivion in the past year.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.